CO5180574A1 - Micofenolato mofetil en asociacion con peg-inf-a - Google Patents

Micofenolato mofetil en asociacion con peg-inf-a

Info

Publication number
CO5180574A1
CO5180574A1 CO00059914A CO00059914A CO5180574A1 CO 5180574 A1 CO5180574 A1 CO 5180574A1 CO 00059914 A CO00059914 A CO 00059914A CO 00059914 A CO00059914 A CO 00059914A CO 5180574 A1 CO5180574 A1 CO 5180574A1
Authority
CO
Colombia
Prior art keywords
peg
association
inf
mofetil mycophenolate
ifn
Prior art date
Application number
CO00059914A
Other languages
English (en)
Inventor
Mary Catherine Graves
Friederike Zahm
Stephen Christopher Partington
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5180574A1 publication Critical patent/CO5180574A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una combinación de una cantidad terapéuticamente efectiva de IFN-alfa o PEG-IFN-alfa en asociación con una cantidad terapéuticamente efectiva de una sal farmacéuticamente aceptable o profármaco de ácido micofenólico para ser usada en la preparación de medicamentos para tratar pacientes con enfermedad hepática .
CO00059914A 1999-08-13 2000-08-10 Micofenolato mofetil en asociacion con peg-inf-a CO5180574A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
CO5180574A1 true CO5180574A1 (es) 2002-07-30

Family

ID=26153083

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00059914A CO5180574A1 (es) 1999-08-13 2000-08-10 Micofenolato mofetil en asociacion con peg-inf-a

Country Status (9)

Country Link
US (1) US20010046957A1 (es)
KR (1) KR20020020809A (es)
AR (1) AR025549A1 (es)
CO (1) CO5180574A1 (es)
HK (1) HK1048951A1 (es)
HR (1) HRP20020118A2 (es)
IL (1) IL147612A0 (es)
MA (1) MA26814A1 (es)
NO (1) NO20020704D0 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142495A1 (en) * 2003-10-09 2005-06-30 David Peter Van Heerden Methods of controlling multilayer foil ignition
US7441688B2 (en) 2003-11-04 2008-10-28 Reactive Nanotechnologies Methods and device for controlling pressure in reactive multilayer joining and resulting product
US7121402B2 (en) * 2003-04-09 2006-10-17 Reactive Nano Technologies, Inc Container hermetically sealed with crushable material and reactive multilayer material
WO2003030613A2 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
WO2005005092A2 (en) * 2003-05-13 2005-01-20 Reactive Nanotechnologies, Inc. Method of controlling thermal waves in reactive multilayer joining and resulting product
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US20090035268A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors

Also Published As

Publication number Publication date
HRP20020118A2 (en) 2003-12-31
US20010046957A1 (en) 2001-11-29
NO20020704L (no) 2002-02-12
IL147612A0 (en) 2002-08-14
HK1048951A1 (zh) 2003-04-25
KR20020020809A (ko) 2002-03-15
MA26814A1 (fr) 2004-12-20
AR025549A1 (es) 2002-12-04
NO20020704D0 (no) 2002-02-12

Similar Documents

Publication Publication Date Title
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
SE8202172L (sv) Topiska farmaceutiska kompositioner
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
CO5190688A1 (es) Formas farmaceuticas de administracion oral al menos parcialmente retardadas cuya sustancia activa tramadol se encuentra al menos parcialmente en forma de compuesto formado in situ con una hidrosolubilidad 100 mg/ml, y procedimientos para su preparac
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
TR200200401T2 (tr) PEG-IFN-a ile birlikte mikofenolat mofetil
NO20003313L (no) Terapeutiske midler
CO5180574A1 (es) Micofenolato mofetil en asociacion con peg-inf-a
PE20020387A1 (es) Uso de una combinacion de salmeterol y fluticasona
AR041069A1 (es) Composicion de tolterodina liquida oral
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
DK0484112T3 (da) Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum
SE0000303D0 (sv) Novel compounds
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
DE69524388D1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
FR2720944B1 (fr) Composition thérapeutique ou diététique sous forme de gel médicamenteux pour l'administration à des animaux de compagnie.

Legal Events

Date Code Title Description
FC Application refused